No­var­tis joins forces with Al­ler­gan, push­ing a NASH com­bo in­to late-stage de­vel­op­ment

Look­ing to leapfrog some in­tense com­pe­ti­tion to field new drugs for NASH and fat­ty liv­er dis­ease, phar­ma gi­ant No­var­tis has struck a deal to part­ner with Al­ler­gan on a new com­bo ap­proach that will start out in a Phase IIb tri­al.

No­var­tis is com­bin­ing an FXR ag­o­nist with Al­ler­gan’s ceni­crivi­roc — CVC — for the treat­ment of non-al­co­holic steato­hep­ati­tis. And they’re keep­ing the num­bers side of the arrange­ment un­der wraps.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.